Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Tesamorelin Dosing at 50–64: Adult Label, Missing Subgroup

By
Published Updated Last reviewed
5 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • FDA-labeled population / adults with HIV and excess abdominal fat from lipodystrophy
  • Pivotal trial age range / 18–65
  • Mean age in both pivotal studies / 48
  • Published age-50–64 dose comparison / not identified
  • WR and SV / different strengths, preparation, storage, and labeled doses
  • Formulation interchangeability / not substitutable
  • Use information over age 65 / none in the label
  • Medical review / current review of this revision is pending

“Adult” Is the Label Category; 50–64 Is an Evidence Question

The current EGRIFTA WR label states:

“There is no information on the use of EGRIFTA WR in patients greater than 65 years of age.”

The issuer is FDA through the approved prescribing information. The sentence defines a data gap above 65; it does not establish equal risk below 65, prohibit every older patient's use, or endorse EGRIFTA or HealthRX.com (label section 8.5, Geriatric Use).

A reader aged 50–64 is within the adult indication and within the pivotal studies' 18–65 eligibility range. That is not the same as a reported age-50–64 subgroup analysis.

Figure 1

Ages in the EGRIFTA pivotal trials: enrolled from 18 to 65, mean 48

Ages in the EGRIFTA pivotal trials: enrolled from 18 to 65, mean 48Range chart of ages in the two pivotal EGRIFTA trials: the main inclusion criterion was age 18 to 65 years in both; the mean age at baseline was 48 years in Study 1 (412 randomized) and 48 years in Study 2 (404 randomized). The labels say there is no information on use above age 65.Main inclusion criterion, both pivotal trials18–65 yearsno label information on use above 65Study 1, mean age at baseline (412 randomized)48 yearsStudy 2, mean age at baseline (404 randomized)48 years020406080Age (years)
Ages in the EGRIFTA pivotal trials: enrolled from 18 to 65, mean 48Range chart of ages in the two pivotal EGRIFTA trials: the main inclusion criterion was age 18 to 65 years in both; the mean age at baseline was 48 years in Study 1 (412 randomized) and 48 years in Study 2 (404 randomized). The labels say there is no information on use above age 65.Main inclusion criterion, bothpivotal trials18–65 yearsno label information on use above 65Study 1, mean age at baseline (412randomized)48 yearsStudy 2, mean age at baseline (404randomized)48 years020406080Age (years)
From the clinical studies section of the current EGRIFTA WR and SV labels. Both pivotal trials (412 and 404 randomized adults with HIV and excess abdominal fat) had age 18 to 65 years as a main inclusion criterion, and the mean age at baseline was 48 in each. The labels give no results by age group; the geriatric-use section says there is no information on use above 65, and pharmacokinetics in elderly patients have not been established. Both trials gave a 2 mg dose of the earlier 1 mg/vial formulation, not WR or SV. Sources: EGRIFTA WR prescribing information, section 14, Study 1, Study 2 [1]; EGRIFTA SV prescribing information, section 14, section 8.5 [4].
Show the numbers behind this chart
Ages in the EGRIFTA pivotal trials: enrolled from 18 to 65, mean 48
Trial measureLow (years)High (years)Note
Main inclusion criterion, both pivotal trials1865no label information on use above 65
Study 1, mean age at baseline (412 randomized)4848
Study 2, mean age at baseline (404 randomized)4848

The Age-and-Formulation Extraction

Evidence questionWhat the source reportsWhat remains unresolved
Were people 50–64 eligible?Yes; pivotal studies enrolled ages 18–65Number exposed, dose response, and adverse events specifically at 50–64
Was the cohort centered on young adults?No; mean age was 48 in both studiesDistribution across later decades and statistical power by age
Does the label give an age-50–64 adjustment?No separate age adjustment appearsWhether individual comorbidity or co-medication changes benefit-risk
What about age above 65?Label says no use informationPK, efficacy, and safety in that population
Can WR and SV amounts be swapped?No; the label says they are not substitutableA conversion outside each product's instructions
Did a population PK model find age effects?No clinically relevant covariate within a 38-person studied rangeA dedicated older-adult PK or outcome study

This is a claim audit, not a personal dose table.

The Formulation Difference Is Larger Than the Age Claim

The March 2025 label describes EGRIFTA WR as an 11.6 mg multi-dose vial with a labeled 1.28 mg daily injection. EGRIFTA SV uses a 2 mg single-dose vial and separate preparation and storage instructions. FDA explicitly says the two formulations and strengths are not substitutable (EGRIFTA WR section 2.1).

The legacy page presented a universal “2 mg once daily” answer and then added age-specific monitoring. That collapses product identity and age evidence into one number.

What the Adult Trials Actually Contribute

The two pivotal studies randomized 412 and 404 adults with HIV, lipodystrophy, and excess abdominal fat. Both reported a mean age of 48, defined metabolic exclusions, and used the earlier 2 mg formulation for 26 weeks, with extension follow-up (FDA label section 14; PMID 20554713).

A 38-person population PK analysis found no clinically relevant age covariate within the range studied. That supports its model, not a blanket conclusion that age never matters or that every comorbidity permits the same plan (PMID 25358450; DOI 10.1007/s40262-014-0202-x).

Label warnings still require patient-specific attention to active malignancy, pituitary-axis disruption, glucose status, persistent IGF-1 elevation, fluid retention, hypersensitivity, and interacting medicines. None becomes an age-50–64 protocol merely because prevalence may change with age.

Figure 2

EGRIFTA's neoplasm warning step by step, as the WR and SV labels set it out

Decision diagram. First: is there an active malignancy? If yes, EGRIFTA is contraindicated, and any earlier malignancy must be inactive with its treatment complete before starting. Second: is there a history of a neoplasm? For a treated and stable malignancy, start only after careful evaluation of benefit against the risk of re-activation; for a non-malignant neoplasm, start after careful evaluation of the potential benefit; with no history, the labels still ask for careful thought because of the higher background risk of malignancies in HIV-positive patients. During treatment, stop EGRIFTA if there is any evidence of recurrent malignancy.
From section 5.1 and the contraindications of the current EGRIFTA WR and SV labels, which use the same wording. The caution about new cancers rests on the higher background risk of malignancies in people with HIV; the section gives no age cut-off. The chart restates the labels' steps for the prescriber's decision; it does not assess anyone's cancer risk. Sources: EGRIFTA WR prescribing information, section 5.1, section 4 [1]; EGRIFTA SV prescribing information, section 5.1 [4].
Text version of this diagram
  1. Is there an active malignancy?
    • Yes: Contraindicated: the labels say not to treat active malignancy with EGRIFTA. Any earlier malignancy must be inactive, with treatment complete, before starting.
    • No: Go to the next question.
  2. Is there a history of a neoplasm?
    • Treated, stable malignancy: Start only after careful evaluation of the benefit against the risk of the malignancy re-activating.
    • Non-malignant neoplasm: Start after careful evaluation of the potential benefit.
    • None: The labels still ask for careful thought because of the higher background risk of malignancies in HIV-positive patients.
  3. During treatment: Stop EGRIFTA if there is any evidence of recurrent malignancy.
  4. Why the labels are cautious: EGRIFTA releases the body's own growth hormone, which the labels call a known growth factor.

What a Real 50–64 Analysis Would Need

A decision-grade subgroup would report participants and exposure by age band, formulation, HIV regimen, baseline glucose status, malignancy history, kidney and liver function, discontinuations, adverse events, VAT response, and uncertainty around each estimate. The sources cited here do not publish that extraction.

The older-adult safety page examines the risk evidence without turning it into a dose. The renal-impairment review addresses another population with unestablished PK, and the levothyroxine interaction audit separates mechanism from documented adjustment.

The evidence-weighted conclusion is therefore narrow: follow the exact approved product's label within its indication; do not invent an age-50–64 change or infer certainty for people over 65.

Medical review of this revision is pending. FDA, NLM, sponsors, investigators, institutions, and authors do not endorse tesamorelin, HealthRX.com, or this page.

Frequently asked questions

Does tesamorelin have a special dose for ages 50 to 64?
No age-50–64 adjustment appears in the current label, and no distinct dose-response analysis for that band was identified. That does not replace individual prescribing judgment.
Can EGRIFTA WR and EGRIFTA SV doses be converted directly?
No. FDA labeling says the formulations and strengths differ and are not substitutable; each product has its own preparation and administration instructions.
What does the label say about patients over 65?
It says there is no information on EGRIFTA WR use in patients greater than 65 years of age.
Did the pivotal trials include older adults?
They enrolled adults ages 18–65 and had a mean age of 48, but the cited results do not provide a complete age-50–64 subgroup extraction.

References

  1. U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin) Prescribing Information. Revised March 2025; Reference ID 5557578. Quoted passage: section 8.5, only sentence. See also sections 2.1, 5, 12.3, and 14. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
  2. Falutz J; Mamputu JC; Potvin D; Moyle G; Soulban G; Loughrey H; Marsolais C; Turner R; Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of clinical endocrinology and metabolism. 2010 Sep;95(9):4291-304. DOI 10.1210/jc.2010-0490. PMID 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
  3. González-Sales M; Barrière O; Tremblay PO; Nekka F; Mamputu JC; Boudreault S; Tanguay M. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clinical pharmacokinetics. 2015 Mar;54(3):285-94. DOI 10.1007/s40262-014-0202-x. PMID 25358450. https://pubmed.ncbi.nlm.nih.gov/25358450/
  4. Theratechnologies Inc., via DailyMed. EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: prescribing information, patient information and instructions for use. SPL version 9, effective 2026-07-29.
A highlighted later-middle-age window leads to an empty subgroup frame, an older-age zone sits beyond the evidence boundary, and separate vial-formulation tracks stop at a wall.
HealthRX evidence illustration: A highlighted later-middle-age window leads to an empty subgroup frame, an older-age zone sits beyond the evidence boundary, and separate vial-formulation tracks stop at a wall. Image: HealthRX.com custom clinical image